Outlining Progress Against Strategic Objectives
Avacta Group PLC (AIM:AVCT) Management Team Appointments
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
Avacta Group PLC (AIM:AVCT) New Response in Phase 1b Trial
New Response in the FAP-Dox (AVA6000) Phase 1b Trial
Avacta Group PLC (AIM:AVCT) Preliminary Full Year 2024 Results
Preliminary Results for the Year Ended December 31, 2024
Avacta Group PLC (AIM:AVCT) Avacta Change in Prelim Date Part 2
Update on timing of preliminary results announcement
Traders Cafe with Zak Mir: Bulletin Board Heroes, Wednesday 28th May 2025
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Gold, Altona Rare
Avacta Group PLC (AIM:AVCT) Board appointments
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the appointments of David Bryant and
Avacta Group PLC (AIM:AVCT) Update on timing of preliminary results
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces that the preliminary results for
Avacta Group PLC (AIM:AVCT) Notice of Results
Investor Presentation via Investor Meet Company
Avacta Group PLC (AIM:AVCT) Investor Webinar on 15 May 2025 at 6.00 pm (BST).
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that Dr Christina
Avacta Group Plc (AIM:AVCT) A Company Developing Next-Generation Cancer Therapies
Avacta Group plc (AVCT) is a life sciences company developing next-generation cancer therapies that deliver powerful anti-tumour payloads directly to the tumour site.
Avacta Group PLC – Avacta presents preclinical data at AACR
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical